Zurich is one of the world's leading wealth management centers, Basel is home to two of the largest pharmaceutical companies on earth, and ETH Zurich and EPFL together form one of the strongest technical research bases in Europe. UBS, Roche, Novartis, and Switzerland's federal research institutes all generate O-1A extraordinary ability records — and Switzerland holds one of the oldest E-2 treaties with the US, dating to 1850, giving founders and investors an additional option.
Three sectors where Swiss O-1A records develop at scale.
Switzerland concentrates an unusual density of globally significant institutions in a small country. Zurich is one of the world's premier wealth management centers, and UBS — now Switzerland's dominant global bank following its 2023 acquisition of Credit Suisse — anchors a private banking and asset management sector that employs Swiss nationals in roles with documented compensation and client-advisory records well above typical benchmarks. Basel, less than an hour from Zurich by train, is the headquarters of Roche and Novartis, two of the largest pharmaceutical companies in the world by R&D investment, generating scientists with deep patent portfolios and publication records.
A third strand is academic and technical research: ETH Zurich — the university where Einstein studied and later taught — is consistently ranked among the top handful of universities in the world, particularly in engineering, physics, and computer science, and its sister institution EPFL in Lausanne holds comparable rank. Switzerland's E-2 treaty with the US is among the oldest in force, rooted in an 1850 treaty of friendship, commerce, and navigation, giving Swiss founders and investors a capital-driven alternative alongside the merit-driven O-1A, EB-1A, and NIW categories covered here.
UBS & Swiss wealth management
Switzerland's dominant global bank post-Credit Suisse acquisition, plus numerous Swiss private banks; wealth management professionals anchor to critical role (director/MD-level titles), high salary (benchmarked against US pay bands), and original contributions (advisory frameworks adopted within the firm).
Roche & Novartis
Basel-headquartered global pharmaceutical majors with substantial R&D operations; scientists qualify through original contributions (drug candidates or formulation methods advanced through clinical development, documented with patents), scholarly articles (Nature Medicine, The Lancet), and critical role at the principal scientist or director level.
ETH Zurich
Consistently ranked among the top universities in the world, particularly in engineering, physics, and computer science; faculty and researchers satisfy original contributions, scholarly articles, judging through peer review or Swiss National Science Foundation grant panels, and critical role through professorships or senior research positions.
EPFL
ETH Zurich's sister federal institute in Lausanne, similarly ranked among the world's top technical universities with particular strength in engineering and life sciences; researchers build O-1A records through the same evidentiary anchors as ETH Zurich faculty.
E-2 treaty available (since 1850)
One of the oldest US bilateral treaties of commerce still in force; Swiss founders and investors with sufficient capital can pursue E-2 as an alternative or complement to the merit-based O-1A, EB-1A, and NIW categories covered here.
Broader Swiss life sciences cluster
Beyond Roche and Novartis, the Basel and Zurich life sciences ecosystem includes numerous biotech companies and research institutes, generating a deep bench of scientists with patent portfolios and clinical development experience relevant to O-1A filings.
Eligibility criteria
The O-1A criteria for Swiss professionals.
Three of eight criteria must be satisfied. For Swiss professionals, the criteria most commonly satisfied differ by sector — banking cases lean on high salary, critical role, and original contributions; pharma cases lean on contributions, articles, and judging; academic cases lean on articles, contributions, and judging. Three to five well-documented criteria is the goal.
01 — PRIZES
Awards & prizes
Swiss National Science Foundation prizes, Latsis Prize, pharmaceutical industry recognitions, and banking and finance sector awards from Swiss financial press.
02 — MEMBERSHIP
Exclusive membership
Swiss Academy of Sciences membership; membership requiring outstanding achievement as judged by recognized experts; editorial board service on major peer-reviewed journals.
03 — PRESS
Published material about the person
Neue Zürcher Zeitung and Finews for Swiss finance and business coverage; Nature News and STAT News for pharma and biotech coverage; Swiss and international trade press for technology and research.
04 — JUDGING
Judging others' work
Swiss National Science Foundation grant review panels; peer review for Nature, Cell, or leading finance journals; editorial board service; conference program committee service.
05 — CONTRIBUTIONS
Original contributions of major significance
An advisory framework or investment strategy adopted within a Zurich bank; a drug candidate or formulation method advanced through clinical development at Roche or Novartis; a research method adopted across the field at ETH Zurich or EPFL.
06 — ARTICLES
Scholarly articles
Publications in Nature Medicine, The Lancet, or the Journal of Medicinal Chemistry for pharma scientists; field-leading journals and conference proceedings for ETH Zurich and EPFL researchers.
07 — CRITICAL ROLE
Critical or essential role
Director or MD at UBS or a Swiss private bank; principal scientist or director at Roche or Novartis; professorship or senior research position at ETH Zurich or EPFL.
08 — HIGH SALARY
High salary
Senior Zurich banking and pharma compensation, benchmarked against equivalent US occupational pay bands — Swiss compensation for top-tier finance and R&D roles frequently translates into strong US percentiles once properly documented.
Swiss O-1A profiles
What qualifying records look like here.
Representative profiles from Swiss O-1A petitions. Identifying details have been generalized.
Executive Director, Wealth Management
Global bank — Zurich
Cross-border advisory for ultra-high-net-worth family offices
Manages CHF 900M+ in assets under advisory across 30+ family office relationships
Compensation in the 92nd percentile per Swiss private banking survey data
Profiled in Neue Zürcher Zeitung on family office advisory trends
Advisory framework adopted as a template across the regional team
Criteria satisfied: critical role (ED-level wealth management position), high salary, press (NZZ), contributions (advisory framework adoption, documented with internal records and expert letters).
Principal Scientist
Global pharmaceutical company — Basel
Small-molecule formulation strategies for oncology candidates
16 US and EU patents; 13 publications in Journal of Medicinal Chemistry
Lead formulation scientist on 2 candidates advanced to Phase II
Peer reviewer for the Journal of Medicinal Chemistry
Compensation at 90th percentile per pharmaceutical industry R&D survey data
Criteria satisfied: contributions (formulation methods advanced through clinical development, documented with patents and expert letters from medicinal chemistry faculty), articles (Journal of Medicinal Chemistry), judging (peer review), high salary.
Associate Professor
ETH Zurich — Department of Computer Science
Novel optimization methods for distributed machine learning systems
20 publications; senior-author papers at NeurIPS, ICML, and ICLR
2,400+ citations; method adopted by 5+ independent research groups
Swiss National Science Foundation grant as principal investigator
ICML area chair; invited speaker at 3 international AI conferences
Criteria satisfied: articles (NeurIPS/ICML/ICLR), contributions (method adoption and citation record), judging (ICML area chair), critical role (ETH Zurich faculty position at a globally top-ranked department).
O-1A and the oldest E-2 treaty
Why merit often outperforms capital for Swiss applicants.
Switzerland's E-2 treaty with the US is one of the oldest in force, but E-2 still requires an active, substantial investment and ongoing direction of the enterprise, and it does not itself lead to a green card. For Swiss professionals in banking, pharma, and research whose personal record — compensation, patents, publications, or institutional prestige — already tells a strong individual story, O-1A is often the better-positioned category, because it pairs directly with an EB-1A or EB-2 NIW filing using the same evidentiary record.
Switzerland's concentration of globally recognized institutions — UBS, Roche, Novartis, ETH Zurich, and EPFL — generates exactly the kind of documented critical roles, high compensation, and original contributions that O-1A requires. Premium processing (15 business days) is commonly used given the pace of Swiss finance and pharma hiring cycles.
Treaty status
Switzerland holds one of the oldest E-2 Treaty Investor agreements with the United States, dating to an 1850 treaty of friendship, commerce, and navigation. Swiss founders and investors can pursue E-2 as a capital-driven alternative. O-1A remains the stronger long-term choice for professionals with a documented individual achievement record who want a direct path to a green card.
FAQ
Switzerland O-1A questions.
Yes, and it is one of the oldest such treaties in force — the underlying treaty dates to 1850. Swiss citizens are eligible for E-2 status when investing in and actively directing a bona fide US enterprise. E-2 is capital-driven, while O-1A, EB-1A, and EB-2 NIW are merit-driven and require no investment. Swiss banking, pharma, and research professionals with a strong individual record often find O-1A a stronger and more durable option.
Yes. Zurich is one of the world's leading wealth management centers, anchored by UBS following its 2023 acquisition of Credit Suisse. Swiss nationals in private banking and wealth management build O-1A records through critical role (director/MD-level titles), high salary (benchmarked against US pay bands), and original contributions (advisory frameworks adopted within the firm).
Yes. Roche and Novartis, both headquartered in Basel, are two of the largest pharmaceutical companies in the world by R&D investment. Evidentiary anchors include original contributions (drug candidates or formulation methods advanced through clinical development, documented with patents), scholarly articles (Nature Medicine, The Lancet), critical role (principal scientist or director-level R&D position), and high salary.
ETH Zurich is consistently ranked among the top universities in the world, particularly in engineering, physics, and computer science. Faculty and researchers satisfy O-1A criteria through original contributions, scholarly articles, judging (peer review or Swiss National Science Foundation grant panel service), and critical role (a professorship or senior research position). ETH Zurich's institutional prestige provides an unusually strong distinguished-organization anchor.
Yes. EPFL, in French-speaking Switzerland, is ETH Zurich's sister federal institute and similarly ranked among the world's top technical universities, with particular strength in engineering and life sciences. EPFL researchers build O-1A records through the same evidentiary anchors as ETH Zurich faculty — original contributions, scholarly articles, judging, and critical role.
